Investigational; Lilly says it is not available for public use and remains under clinical study.
Open related pageComparison
retatrutide vs tirzepatide
Retatrutide and tirzepatide are not interchangeable. This comparison is not a conversion chart, switching protocol, or treatment recommendation.
Direct answer
Retatrutide is Lilly's investigational triple agonist. Tirzepatide is a different GIP and GLP-1 receptor agonist with FDA-approved prescription products for specific labeled uses.
FDA-approved prescription products exist for specific labeled uses; label and prescriber context matter.
Open related pageDo not self-switch between GLP products or experimental products based on comparison pages.
Open related pageWhat to know before acting on this search
- Retatrutide activates GIP, GLP-1, and glucagon receptors in Lilly's description.
- Tirzepatide activates GIP and GLP-1 receptors and has FDA-approved prescription labels for specific uses.
- Retatrutide trial results are not an approved label and do not establish public-use dosing.
- Side effects, contraindications, insurance, and monitoring require clinician context.
Safety and compliance notes
- Do not use retatrutide trial data as a personal substitute for an approved tirzepatide label.
- Do not combine or switch incretin drugs without a prescriber.
- Online retatrutide listings do not become safer because tirzepatide products are approved.
Safer next step
Use the longer comparison guide for evidence context, then discuss approved treatment paths with a qualified healthcare provider.
Medical disclaimer
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. FDA-approved medicines such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.